Introduction
Cancer treatment has increasingly moved toward precision medicine, where therapies are designed to target specific genetic mutations that drive tumor growth. For some patients with melanoma, colorectal cancer, or non-small cell lung cancer, identifying a BRAF mutation may open the door to targeted therapies that work differently from traditional chemotherapy.
Braftovi is a targeted cancer therapy developed to block abnormal BRAF proteins involved in cancer cell growth. The medication is specifically used in cancers that contain certain BRAF V600 mutations confirmed through FDA-approved molecular testing.
The medication is approved for use in combination treatment regimens involving other cancer therapies such as binimetinib or cetuximab, depending on the type of cancer being treated. By targeting abnormal BRAF signaling pathways, Braftovi may help slow tumor growth, improve disease control, and delay cancer progression in eligible patients.
Braftovi is administered orally as capsules, allowing many patients to take treatment at home while remaining under close supervision from oncology specialists. However, targeted oncology medications often require specialty pharmacy coordination, ongoing imaging studies, laboratory monitoring, and management of combination therapy regimens.
Although precision oncology therapies may provide important treatment benefits, specialty cancer medications can also create significant financial concerns. Patients may face high out-of-pocket expenses, insurance prior authorization requirements, specialty pharmacy costs, and ongoing treatment monitoring expenses throughout therapy.
Prescription Hope helps eligible individuals navigate the enrollment process for medications like Braftovi and offers advocacy and support for patients looking to access affordable medications, such as Braftovi.
Understanding how Braftovi works, possible treatment benefits, side effects, and available medication access resources can help patients feel more informed when discussing treatment options with their oncology provider.
What Is the Braftovi Patient Assistance Program?
The Braftovi Patient Assistance Program offers qualified patients access to affordable Braftovi.
Pharmaceutical manufacturers understand their brand-name medications may be too expensive for most Americans to pay out of pocket.
Therefore, they have come up with a solution. They offer patient assistance programs, which provide access to affordable brand-name medications for those who qualify.
Unfortunately, many of these programs have been known to have complex application processes. Patients report feeling overwhelmed and frustrated.
Prescription Hope has an answer.
How Expert Advocates Help Make Braftovi More Affordable
Professional Application Management
Prescription Hope provides patients with professional application management. We advocate on patients’ behalf throughout the patient assistance program application process.
Braftovi Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Predictable Monthly Pricing
We do all this and more for a simple $70.00 per month, per medication. No hassles, hidden fees, or upcharges.
Those who do not qualify for their intended program may still benefit from Prescription Hope’s services. We work to find alternative savings options. Some of those may include substitute medications and their programs, discount cards, coupons, and more.
We are not an insurance company, discount card, or coupon. We are a medication access service devoted to supporting you in your journey to access affordable medications.
Ongoing Advocacy and Refill Support
We continue to handle the necessary tasks related to participating in a patient assistance program. Our team manages refill schedules, document updates, program monitoring, and yearly renewals.
Braftovi Patient Assistance Eligibility
Those curious about whether they’re eligible for oncology assistance should enroll with Prescription Hope to determine qualification.
While each program maintains strict qualification standards, the standards vary between programs. Some areas of criteria include:
Income: Requirements regarding income vary between programs.
Insurance: Insurance coverage status may vary between specific programs.
U.S. Residency: All patients must be legal U.S. residents to qualify.
Prescription: All patients must also maintain a valid prescription for the medication they intend to apply for.
Simple Enrollment With Expert Support
Starting Your Journey
Those who wish to enroll in Braftovi assistance need look no further than Prescription Hope for their specialty pharmacy assistance.
Enrolling in Prescription Hope takes 6 steps:
- Submit Information: Our online enrollment form is simple, secure, and only takes a few minutes to complete.
- Advocate Contact: Following submission of your form, a patient advocate will contact you within 1-2 business days.
- Document Collection: After prequalification, we’ll collect the necessary documents.
- Provider Coordination: We also gather all necessary signatures.
- Program Submission: We submit your application packet and follow up with the manufacturer.
- Medication Delivery: After approval, a patient can typically expect to see their medication shipped directly to them or their doctor within 2 weeks.
Prescription Hope does not handle any medications. We are not a pharmacy or manufacturer. We are a support and advocacy service.
Medication Delivery and Ongoing Support
After initial delivery, Prescription Hope continues to handle tasks such as refill scheduling, document updates, and yearly renewals.
Understanding Braftovi
How Braftovi Works
Braftovi works by blocking mutated BRAF proteins that help certain cancer cells grow and divide uncontrollably.
In cancers with BRAF V600 mutations, the abnormal BRAF protein becomes overactive and continuously signals cancer cells to grow. Braftovi inhibits this abnormal signaling pathway, which may help:
- Slow tumor growth
- Reduce cancer cell survival
- Help shrink tumors
The medication is classified as a BRAF kinase inhibitor and is considered a precision oncology therapy because it targets cancers with specific genetic mutations.
Braftovi is commonly used in combination with other targeted therapies to improve treatment effectiveness and help delay resistance mechanisms that may develop over time.
The medication is administered orally as capsules, usually once daily, and is managed under the supervision of oncology specialists experienced in targeted cancer therapies.
What Conditions Does Braftovi Treat?
Braftovi is FDA-approved for use in certain cancers with confirmed BRAF mutations, including:
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (used in combination with binimetinib)
- Metastatic colorectal cancer with a BRAF V600E mutation (used in combination with cetuximab)
- Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation (used in combination with binimetinib)
Treatment eligibility generally requires FDA-approved testing to confirm the presence of a BRAF mutation before therapy begins.
BRAF mutations are genetic changes that can promote uncontrolled cancer cell growth in certain tumors. Because Braftovi specifically targets these mutations, molecular testing is an important part of determining whether treatment may be appropriate.
Healthcare providers evaluate cancer type, mutation status, prior treatments, overall health, and treatment goals when considering Braftovi therapy.
Benefits of Treatment
For eligible patients with BRAF-mutated cancers, Braftovi may provide important targeted treatment benefits.
Potential benefits of Braftovi treatment may include:
- Targeted treatment for cancers with BRAF mutations
- Delayed cancer progression in some patients
- Improved disease control when used in combination regimens
- Objective response rates demonstrated in clinical studies
- Oral administration at home
- An additional targeted treatment option for advanced cancers with BRAF mutations
Clinical studies demonstrated improved response rates and progression-free survival in many patients receiving Braftovi-based treatment regimens.
Treatment outcomes vary depending on cancer type, disease progression, mutation status, prior therapies, and individual patient response. Patients generally require ongoing imaging studies and laboratory monitoring throughout therapy.
Important Safety Information and Side Effects
Like all targeted cancer therapies, Braftovi may cause side effects and carries important safety considerations. Patients should discuss the risks and benefits of treatment with their healthcare provider before beginning therapy.
One important safety concern involves the development of new primary malignancies, including new melanomas and cutaneous squamous cell carcinoma. Regular dermatologic evaluations are recommended during and after treatment.
Common side effects associated with Braftovi may include:
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Joint pain
- Rash
- Fever
- Muscle pain
- Headache
- Changes in liver enzyme levels
Side effects may vary depending on the combination therapies used alongside Braftovi.
Additional important safety concerns may include:
- Decreased left ventricular ejection fraction (LVEF) and cardiac effects
- Serious hemorrhagic events
- Serious eye problems, including uveitis and retinal disorders
- Liver toxicity
- QT prolongation and heart rhythm abnormalities
- Severe skin reactions
- Embryo-fetal toxicity during pregnancy
Patients should promptly report symptoms such as:
- Vision changes
- Chest pain
- Fainting
- Severe rash
- Unusual bleeding
- Signs of liver problems
Regular monitoring during treatment may include:
- Skin examinations
- Liver function testing
- Cardiac monitoring
- Eye evaluations
- Electrolyte monitoring in patients at risk for QT prolongation
Certain CYP3A-related drug interactions may require dose adjustments or careful monitoring. Patients should discuss all medications, vitamins, and supplements with their healthcare provider before starting treatment.
Braftovi does not currently carry an FDA boxed warning.
Access to Multiple Medications
Looking for specialty medication assistance as well as other medications? Need more than targeted cancer therapy support?
Prescription Hope helps patients every day who require multiple medications. No matter how many you qualify for, we can help with your access. For every medication you qualify for, our service remains a simple and low $70.00 per med, per month.
Why Choose Prescription Hope for Braftovi Assistance
Experienced Advocacy Support
For 20 years, Prescription Hope has supported patients with expertise and compassion. Our Florida-based staff works alongside you at every step in the patient assistance journey.
Ongoing Medication Management
We continue advocating for you even after your initial shipment is delivered. We manage refill scheduling, document updates, yearly renewals, and more.
Transparent Monthly Pricing
Our service fee is predictable, transparent, and low: $70.00 per month, per med. That’s it.
Nationwide Medication Access Support
We operate in a network of manufacturers and healthcare providers that gives us access to hundreds of brand-name medications.
If you’re looking for affordable Braftovi assistance or specialty oncology medication access, then be sure to enroll with Prescription Hope and find out how we can help you save on your monthly medication costs.
